These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36251879)

  • 1. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer.
    Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
    Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
    Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
    Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
    Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.
    Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X
    J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
    Shanle EK; Zhao Z; Hawse J; Wisinski K; Keles S; Yuan M; Xu W
    Mol Endocrinol; 2013 Oct; 27(10):1762-75. PubMed ID: 23979844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
    Hinsche O; Girgert R; Emons G; Gründker C
    Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
    Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
    BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
    Alexandrova E; Lamberti J; Saggese P; Pecoraro G; Memoli D; Cappa VM; Ravo M; Iorio R; Tarallo R; Rizzo F; Collina F; Cantile M; Bonito MD; Botti G; Nassa G; Weisz A; Giurato G
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.
    Hamilton N; Márquez-Garbán D; Mah V; Fernando G; Elshimali Y; Garbán H; Elashoff D; Vadgama J; Goodglick L; Pietras R
    Biomed Res Int; 2015; 2015():925703. PubMed ID: 25874233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
    Hamilton N; Marquez-Garban D; Mah VH; Elshimali Y; Elashoff D; Garon EB; Vadgama J; Pietras R
    Crit Rev Oncog; 2015; 20(5-6):373-90. PubMed ID: 27279236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.
    Reese JM; Bruinsma ES; Nelson AW; Chernukhin I; Carroll JS; Li Y; Subramaniam M; Suman VJ; Negron V; Monroe DG; Ingle JN; Goetz MP; Hawse JR
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):E9580-E9589. PubMed ID: 30257941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
    Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer.
    Alexandrova E; Giurato G; Saggese P; Pecoraro G; Lamberti J; Ravo M; Rizzo F; Rocco D; Tarallo R; Nyman TA; Collina F; Cantile M; Di Bonito M; Botti G; Nassa G; Weisz A
    Mol Cell Proteomics; 2020 Feb; 19(2):245-260. PubMed ID: 31792072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
    Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
    Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drivers and suppressors of triple-negative breast cancer.
    Wu W; Warner M; Wang L; He WW; Zhao R; Guan X; Botero C; Huang B; Ion C; Coombes C; Gustafsson JA
    Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34389675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
    Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
    Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer.
    Shanle EK; Onitilo AA; Huang W; Kim K; Zang C; Engel JM; Xu W; Wisinski KB
    Am J Transl Res; 2015; 7(7):1246-59. PubMed ID: 26328009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53.
    Scarpetti L; Oturkar CC; Juric D; Shellock M; Malvarosa G; Post K; Isakoff S; Wang N; Nahed B; Oh K; Das GM; Bardia A
    Oncologist; 2023 Apr; 28(4):358-363. PubMed ID: 36772966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
    Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
    BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.